Wert Leonhard, Chatterjee Anamika, Dogan Günes, Hanke Jasmin S, Boethig Dietmar, Tümler Kirstin A, Napp L Christian, Berliner Dominik, Feldmann Christina, Kuehn Christian, Martens Andreas, Shrestha Malakh L, Haverich Axel, Schmitto Jan D
Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
J Thorac Dis. 2018 Jun;10(Suppl 15):S1696-S1702. doi: 10.21037/jtd.2018.01.27.
Left ventricular assist device (LVAD) (HVAD, Medtronic, Minneapolis, MN, USA) implantation is already a widely accepted treatment option for end-stage heart failure (HF) but also still considered as a rescue therapy for patients suffering from cardiogenic shock. Standard LVAD implantation techniques are often associated with high mortality rates and can result in severe complications, like bleeding or right heart failure (RHF). The aim of our study was to assess the outcome of Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 1 patients (so called "crash and burn" patients) undergoing a LVAD implantation by standard or less invasive surgery.
We performed a retrospective evaluation of the 1-year outcome of 32 consecutive HF patients in cardiogenic shock, who underwent LVAD implantation in our institution. A total of 32 INTERMACS 1 patients were emergently operated. Fourteen patients (group A) were operated by using the "Hannover-VAD-technique", which is widely known to be less invasive (upper hemisternotomy and a left-sided anterolateral thoracotomy). In contrast, 18 patients (group B) were implanted with LVAD by using the standard technique (full sternotomy). The primary endpoint was survival after 1 year without device-related re-operations. Secondary endpoints included combined analyses of rates of RHF, respiratory failure and bleeding during the trial period.
Baseline characteristics were similar in both groups. Survival after 1 year was higher in group A (69.7% 50.0%). Technique-related adverse events (AEs) were also lower in the minimally invasive group, including a lower RHF (35.7% 61.1%) and of further postoperative bleeding requiring surgery (14.3% 33.3%).
LVAD surgery in INTERMACS 1 patients is associated with remarkably good outcome considering the already very high mortality of those patients, and compared to previously reported surgical outcomes. Our study indicates that minimally invasive LVAD implantation in cardiogenic shock decreases mortality and the incidence of postoperative AEs.
左心室辅助装置(LVAD)(HeartWare心室辅助系统,美敦力公司,明尼阿波利斯,明尼苏达州,美国)植入术已成为终末期心力衰竭(HF)广泛接受的治疗选择,但仍被视为心源性休克患者的抢救治疗方法。标准的LVAD植入技术常伴随着高死亡率,并可能导致严重并发症,如出血或右心衰竭(RHF)。我们研究的目的是评估通过标准或微创外科手术进行LVAD植入的机构间机械辅助循环支持注册研究(INTERMACS)1级患者(即所谓的“濒死”患者)的预后。
我们对在我院接受LVAD植入的32例连续性心源性休克HF患者的1年预后进行了回顾性评估。共有32例INTERMACS 1级患者接受了急诊手术。14例患者(A组)采用“汉诺威VAD技术”进行手术,该技术以微创性广为人知(上半胸骨切开术和左侧前外侧开胸术)。相比之下,18例患者(B组)采用标准技术(全胸骨切开术)植入LVAD。主要终点是1年后无装置相关再次手术的生存率。次要终点包括试验期间RHF、呼吸衰竭和出血发生率的综合分析。
两组的基线特征相似。A组1年后的生存率更高(69.7%对50.0%)。微创组的技术相关不良事件(AE)也更低,包括较低的RHF发生率(35.7%对61.1%)和需要手术的进一步术后出血发生率(14.3%对33.3%)。
考虑到INTERMACS 1级患者本已很高的死亡率,与先前报道的手术结果相比,LVAD手术的预后非常好。我们的研究表明,在心源性休克患者中进行微创LVAD植入可降低死亡率和术后AE的发生率。